The Motley Fool··Jonathan PoncianoOncology Biotech Syndax Surges on $6.5M Investment Amid 629% Revenue Spike
Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.
SNDXrevenue growthcancer treatment